Kintara Therapeutics Reminds Stockholders to Vote
Kintara Therapeutics, Inc. (NASDAQ: KTRA) is reaching out to stockholders to emphasize the important deadline for voting on the proposed merger with TuHURA Biosciences. Stockholders are encouraged to make their voices heard by submitting their votes before the specified deadline.
Key Voting Information
Kintara wants to remind stockholders that they need to cast their votes by 11:59 p.m. ET for their opinions to be counted. A majority of the voting power from Kintara's outstanding shares is necessary for the merger with TuHURA Biosciences to move forward.
Why Voting Matters
The company has noted that the voting threshold for approving Proposals 3 and 5 has not yet been reached, and these proposals are crucial for finalizing the merger. Institutional Shareholder Services and Glass Lewis are both recommending a "FOR" vote on these proposals, highlighting how essential they are for the future of the company.
Insights from Leadership
Robert E. Hoffman, Kintara's Chief Executive Officer, has stated that stockholders' votes are critical for the successful execution of the merger. Kintara believes this merger will allow them to combine their oncology technologies and assets, which will help address treatment resistance in cancer care and fast-track their project pipeline through significant financing.
Overview of the Proposals
Proposal 3 aims to amend Kintara's Articles of Incorporation to increase the number of authorized shares, while Proposal 5 discusses relocating Kintara's incorporation from its current state to Delaware. These amendments are designed to equip Kintara for effective growth and operations in the future.
Voting Procedures
Kintara offers several methods for stockholders to cast their votes:
- By Phone: North American stockholders can reach Alliance Advisors at (866)-619-8907, while international voters can call +1 (551) 210-9859 for assistance.
- By Internet: Votes can be cast at www.proxyvote.com with instructions from your broker or bank.
- Changing Votes: Stockholders have the option to change their votes before the deadline by contacting Alliance Advisors as mentioned earlier.
Every stockholder who held shares as of the record date is encouraged to take part in this significant decision, even if they do not currently hold Kintara shares.
About Kintara Therapeutics
Kintara is committed to creating innovative cancer therapies to fulfill unmet medical needs. One of their leading treatments, REM-001, targets cutaneous metastatic breast cancer and has shown encouraging results in earlier clinical trials.
The Importance of the Merger
The merger with TuHURA represents a crucial opportunity for Kintara, aiming to boost its capabilities in oncology treatments. TuHURA is known for its advanced immuno-oncology products, with the goal of improving cancer therapy outcomes. The merger would enable both companies to unite their strengths to enhance their efforts in combating cancer more effectively.
Frequently Asked Questions
What is the voting deadline for Kintara's stockholders?
The voting deadline is 11:59 p.m. ET, which is essential for counting votes regarding the merger with TuHURA.
Why is the merger with TuHURA significant?
This merger aims to strengthen Kintara's capabilities by incorporating TuHURA's advanced technologies, ultimately enhancing treatment options for solid tumors.
Who can I contact for assistance with the voting process?
Stockholders can contact Alliance Advisors for help with the voting process and any questions they may have.
What proposals will be voted on?
Proposals 3 and 5 are vital; they focus on increasing the number of authorized shares and moving Kintara's incorporation from Nevada to Delaware.
How will this merger impact Kintara's future?
Successfully completing the merger is expected to bolster Kintara's financial standing and resource capabilities, with hopes of accelerating the development of cancer treatments.
